Celebrating 20 Years of IP Excellence

Image accompanying blogpost on "Cancerous Battle: Novartis and NATCO clash over Eltrombopag"

Cancerous Battle: Novartis and NATCO clash over Eltrombopag

In a landmark decision, the Delhi High Court overturned an injunction against Natco, allowing them to produce a generic version of Novartis’s cancer drug. The Court held that Novartis’s patent on a specific salt form of the drug (ELT-O) lacked novelty due to its coverage in an earlier patent (IN’176). Continue Reading Cancerous Battle: Novartis and NATCO clash over Eltrombopag

Read more

Intellectual Property, accessibility and public health

Intellectual Property, Accessibility and Public health

On the 30th of July 2020, the international organizations - WIPO, WTO and WHO jointly published a study report titled "Promoting access to medical technologies and innovation - Intersections between public health, intellectual property and trade". This second edition report records the numerous significant developments that have occurred since 2013, when the first edition was published. The 2013 edition of the report may be accessed by clicking here and the 2020 edition of the report may be accessed by…

Read more

WHO - Coronavirus disease (COVID-19) advice for the public

Coronavirus disease (COVID-19) advice for the public – World Health Organization (WHO)

BananaIP team is sharing the latest information provided by World Health Organization (WHO) on the COVID-19 outbreak, available on the WHO website. Most people who become infected experience mild illness and recover, but it can be more severe for others. Take care of your health and protect others by doing the following:   Basic protective measures against the new coronavirus Regularly and thoroughly clean your hands with an alcohol-based hand rub or wash them with soap and water. Why? Washing your hands with…

Read more

pharmaceutical patent x

Extension of Waiver for Pharma Patents until 2033 A.D.

After intense negotiations between the United States and the Group of Least-Developed Countries, the World Trade Organization committee on intellectual property rights finally decided to extend a waiver allowing LDCs from applying and enforcing IP rights on pharmaceutical products until 2033. The consensus among the World Trade Organisation (WTO) members over extension of waivers in respect of pharmaceutical patents for the least developed countries (LDCs) is being held as a major breakthrough in the world of pharmaceutical patents. Following the…

Read more